Core Insights - The company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA, indicating that incremental weight loss is an acceptable primary endpoint for approval [1][10] - The Phase 2b PLATEAU clinical study is planned to start in Q1 2026, focusing on older patients with obesity [1][12] - The company completed a public offering post fiscal year end, raising approximately $23.4 million [1][19] Clinical Development - The Phase 2b QUALITY study demonstrated that enobosarm, when combined with GLP-1 RA, selectively promotes fat loss while preserving lean mass and physical function in older patients [4][17] - The FDA has confirmed that enobosarm 3 mg is an acceptable dosage for future clinical development [11] - The Phase 2b PLATEAU study will evaluate the effects of enobosarm on body weight, physical function, and safety in patients aged 65 and older with a BMI of 35 or higher [12][13] Financial Performance - For fiscal year 2025, research and development expenses increased to $15.6 million from $12.8 million, while general and administrative expenses decreased to $19.9 million from $24.6 million [14] - The operating loss from continuing operations decreased to $24.8 million from $36.2 million [14] - The net loss from continuing operations decreased to $15.7 million, or $1.07 per share, compared to $35.3 million, or $2.61 per share in the previous year [19]

Core Insights - T1 Energy Inc. has commenced construction on its G2_Austin solar cell manufacturing facility, representing an investment of $400 to $425 million aimed at enhancing the U.S. solar supply chain [1][2][3] Group 1: Project Overview - The first phase of the G2_Austin facility is projected to have an annual capacity of 2.1GW of high-efficiency TOPCon solar cells, surpassing the current U.S. manufacturing capacity for silicon-based solar cells [2] - The facility is expected to begin production by the end of 2026 [2] - The second phase of G2 is anticipated to expand capacity to 3.2GW, with potential for further expansion based on demand [5] Group 2: Economic and Employment Impact - The G2_Austin project is expected to create up to 1,800 new advanced manufacturing jobs in Milam County, Texas [3] - This initiative aligns with the Trump Administration's economic policies, focusing on strengthening domestic manufacturing and energy security [3] Group 3: Strategic Importance - T1 Energy's Chairman and CEO emphasized that G2_Austin is central to the company's strategy for establishing an integrated U.S. polysilicon solar supply chain [4] - The solar cells produced at G2_Austin will be utilized in T1's existing 5GW G1_Dallas facility, catering to the demand for domestically produced solar modules [4]

Aspo Plc Managers’ transactions December 17, 2025 at 13.00 EET Aspo Plc - Managers' Transactions - Erkka Repo ____________________________________________ Person subject to the notification requirement Name: Erkka Antero Repo Position: Chief Financial Officer Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677 Notification type: INITIAL NOTIFICATION Reference number: 134432/5/4 ____________________________________________ Transaction date: 2025-12-16 Outside a trading venue Instrument type: SHARE ISIN: ...

VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- BIGG Digital Assets Inc. (“BIGG” or the “Company”) (TSXV: BIGG; OTCQB: BBKCF; WKN: A2PS9W), a leading innovator in the digital assets space and owner of Netcoins, Blockchain Intelligence Group, and TerraZero, is pleased to provide a comprehensive corporate update highlighting recent regulatory, operational and strategic milestones across the organization. Key Messages CRA issues materially reduced Notice of Reassessment for Netcoins’ 2018 GST/HS ...

TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- NorthWest Copper Corp. (“NorthWest” or the “Company”) (TSX-V: NWST) is pleased to report excellent near-surface drill results from two holes completed as part of its 2025 program at the Company’s 100% owned Kwanika project in British Columbia. Results from the two holes exceeded expectations within the Pit Zone, successfully expanding Pit Zone 10 down-dip, helping to define a newly recognized Pit Zone 12, and indicating that these zones remain open along strike and ...

SAN DIEGO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beam Global, (Nasdaq: BEEM), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation, energy security and smart city infrastructure, announced the deployment of seven EV ARC™ off-grid electric vehicle (EV) charging systems for the City of Fresno, California. The systems were deployed at the City’s Municipal Service Center (MSC) Yard and will be used to support charging for the City’s municipal EV fleet.T ...

Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid®-ineligible patients, representing a significant population with few effective treatment options Final data analysis to be reported in January 2026 NEWTOWN, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to hu ...

Core Insights - Shanghai Kohope Medical Devices Co., Ltd. is investing $2.5 million in facility expansion to meet increasing demand for syringes and medical needles in the U.S. and Canada [1][2] - The expansion will result in a 20% increase in production capacity, enabling the company to serve customers in over 50 countries more effectively [2][6] - The new manufacturing lines will increase monthly output to 25 million units and improve delivery times to U.S. healthcare facilities [4][10] Strategic Expansion Details - The expansion includes the installation of advanced automated production equipment with real-time quality control systems [10] - The new lines will focus on high-demand products such as 1ml, 3ml, and 5ml syringes, as well as 21-gauge to 25-gauge medical needles [10] - The new distribution center in Newark, New Jersey, will reduce delivery times from 3-4 weeks to 3-5 business days and provide same-day emergency fulfillment capabilities [4][6] Market Response and Future Growth - The expansion follows a 35% year-over-year increase in North American orders during 2024, driven by demand from various healthcare facilities [16] - The company has secured contracts with three major U.S. healthcare group purchasing organizations (GPOs) effective early 2025 [17] - The global distribution network spans over 50 countries, ensuring consistent supply and fostering long-term relationships with healthcare institutions [17] Commitment to Innovation - The company is advancing research and development initiatives, including a new line of safety-engineered syringes with retractable needles scheduled for market introduction in late 2025 [19] - Shanghai Kohope Medical Devices emphasizes adapting product offerings and capabilities to meet evolving healthcare needs [20] Comprehensive Product Portfolio - The company offers a wide range of syringes and medical needles, accommodating diverse dosage requirements and medical practices [14] - Each product undergoes meticulous quality inspection to ensure compliance with regulatory requirements across different markets [15]

Core Insights - 36Kr Holdings Inc. successfully hosted the WISE 2025 Business Kings Conference, which redefined traditional business conference formats and attracted significant media attention with over 500 million views [1][2][11] Event Overview - The WISE 2025 conference took place on November 27-28, 2025, in Beijing's 798 Art District, featuring a unique seven-act agenda inspired by short plays [1][3] - The event gathered business leaders and innovators from various sectors, including intelligent hardware, artificial intelligence, life sciences, retail, and investment [1][2] Key Highlights - The conference featured a mass-participation AI short play titled "Forging the Dawn," showcasing AI's advancements in creative generation [3] - A live demonstration of Unitree Technology's G1 humanoid robot set a tone of technological innovation for the event [3] Thematic Acts - **Act 1: New Beginnings 2025 and 2035** - Executives shared entrepreneurial journeys and launched Houmo.AI's M50 chip [4] - **Act 2: Challengers and the Tech Wave** - Discussions on technological disruption and the evolution of AI for Science [5] - **Act 3: Embodied Artificial Intelligence** - In-depth discussions on defining embodied AI and its applications [5] - **Act 4: Brand Building** - Introduction of the "Three Constants" brand-building theory and the "Future Super Chinese Brands List" [6] - **Act 5: Tech-empowered Innovation in Consumer Goods** - Showcasing how AI is reshaping the marketing value chain [7] - **Act 6: Global Expansion and Synergy** - AI applications in global expansion scenarios discussed by industry leaders [9] - **Act 7: Outlook on the New Tech Era** - Insights on generational consumption drivers and the computing power revolution [9] Recognition and Support Initiatives - 36Kr unveiled the WISE 2025 Business Kings Annual Honors Lists, recognizing notable figures in China's capital markets [10] - The company launched the IPO Acceleration Camp in partnership with Zhong Lun Law Firm, providing a structured support framework for enterprises [10] Future Commitment - 36Kr aims to deepen its engagement in the industrial ecosystem, focusing on long-term commitment, tech-driven advancement, and innovation [11] - The company plans to support entrepreneurs and help investors identify long-term value opportunities through various initiatives [11]

Core Insights - The company has achieved a booking position of 72% for 2025 capacity, which is approximately 96% of the full-year targeted occupancy [2] - For 2026, 47% of capacity is booked, which is about 8% ahead of the same time last year, with a target of 10-15% growth in Average Cabin Revenue (ACR) across cabin categories [1] - The occupancy rate reached 68%, and ACR increased by more than 15% compared to November 2024 [2] - Total ticket revenue remained consistent with November of the previous year, while ACR is currently 20% above the same time last year for the full year [2] Booking Position - As of now, 72% of the 2025 capacity is booked, indicating strong demand and effective sales strategies [2] - For 2026, the company is targeting a 10-15% growth in ACR, which supports continued revenue growth and EBITDA margin expansion [1] Revenue Performance - ACR has shown significant improvement, increasing by over 15% compared to the previous year [2] - The total ticket revenue aligns with the previous year's performance, indicating stability in revenue generation [2]